Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19881826 | 1.00 | OPRM1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL19058766 | 1.00 | OPRM1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL3274216 | 0.94 | OPRM1 (0.57) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL27858675 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL43343 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL27858674 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL12557215 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL29809913 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| SCHEMBL47340 | 0.84 | ADRB1 (0.53) | OPRM1SLC22A1ADRB1ADRA1AMIF | |
| Hydrochloric Acid SCHEMBL4060357 | 0.82 | ADRB1 (0.52) | OPRM1SLC22A1ADRB1ADRA1AMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2711354-B1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| EP-2233465-B1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | SHANGHAI INST PHARMACEUTICAL IND (CN) | 2017-06-28 | — | — | EP | disclosed |
| EP-2233465-B1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | SHANGHAI INST PHARMACEUTICAL IND (CN) | 2017-06-28 | — | — | EP | disclosed |
| US-9353049-B2 | Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-31 | — | — | US | disclosed |
| US-9353049-B2 | Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-31 | — | — | US | disclosed |
| US-9353049-B2 | Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-31 | — | — | US | disclosed |
| EP-2711354-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2014-03-26 | — | — | EP | disclosed |
| EP-2711354-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2014-03-26 | — | — | EP | disclosed |
| US-20140073809-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20140073809-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-03-13 | — | — | US | disclosed |
| US-8324429-B2 | Preparation method of rivastigmine, its intermediates and preparation method of the intermediates | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2012-12-04 | — | — | US | disclosed |
| US-8324429-B2 | Preparation method of rivastigmine, its intermediates and preparation method of the intermediates | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2012-12-04 | — | — | US | disclosed |
| US-20100286437-A1 | PREPATATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2010-11-11 | — | — | US | disclosed |
| US-20100286437-A1 | PREPATATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2010-11-11 | — | — | US | disclosed |
| US-20100286437-A1 | PREPATATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2010-11-11 | — | — | US | disclosed |
| US-20100286437-A1 | PREPATATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2010-11-11 | — | — | US | disclosed |
| EP-2233465-A1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | Shanghai Institute of Pharmaceutical Industry (CN) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233465-A1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | Shanghai Institute of Pharmaceutical Industry (CN) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233465-A1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | Shanghai Institute of Pharmaceutical Industry (CN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086705-A1 | PREPARATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073809-A1 | PREPARATION METHOD FOR RIVASTIGMINE, INTERMEDIATES THEREOF, AND PREPARATION METHOD FOR SAID INTERMEDIATES | ACHE, PSEN1, CHRM5 | OPRM1 243/4885SLC22A1 4802/4885ADRB1 482/4885 |
| US-20100286437-A1 | PREPATATION METHOD OF RIVASTIGMINE, ITS INTERMEDIATES AND PREPARATION METHOD OF THE INTERMEDIATES | PSEN1, ACHE, PNMT | OPRM1 518/4885SLC22A1 3582/4885ADRB1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.